Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 208362
Company: AMRING PHARMS
Company: AMRING PHARMS
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | AB | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
06/21/2019 | ORIG-1 | Approval | STANDARD |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208362Orig1s000ltr.pdf |
MESALAMINE
SUPPOSITORY;RECTAL; 1GM
TE Code = AB
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
CANASA | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | Yes | AB | 021252 | ABBVIE |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 205654 | ACTAVIS MID ATLANTIC |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 208362 | AMRING PHARMS |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 213377 | ANNORA PHARMA |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 204354 | MYLAN |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 207448 | PHARM SOURCING |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 202065 | SANDOZ |
MESALAMINE | MESALAMINE | 1GM | SUPPOSITORY;RECTAL | Prescription | No | AB | 208953 | ZYDUS PHARMS |